India-bred private equity firm Chrys Capital is set to buy 10 per cent in fast-growing Mankind Pharmaceuticals for $350 million. GIC of Singapore and CPPIB of Canada may co-invest in the deal, likely to be signed this week.

— Business Standard

Desai & Diwanji advised GIC, the sovereign wealth fund of the Government of Singapore led by a team of partner Shreevardhan Sinha and associate Shreya Iyer.

Update 29 May 2019: Platinum Partners advised Capital International led by a team of partner Ankit Majmudar.

Shardul Amarchand Mangaldas and Khaitan & Co also advised.

2018-04-06

Deal value: Approx USD 350 mn

{incomplete}